Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

The administration, which is set to cut the subsidy for the drug benefit program by 40%, says it will negotiate with insurers to ease the financial strain to the millions of seniors on the plan. Plus, ...

Tack on a half-dozen zeros to your CVS receipt and you'll get a sense of the sticker shock afflicting state officials, insurers and hospitals dealing with the soaring cost of prescription drugs in ...

Editors: Story has been updated from original, with material from the president of the Arizona Obesity Organization. Slug: ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...

Medicare is expanding its drug price negotiation program to include 15 more medications, including popular drugs like Ozempic ...

Trump says he could decrease drug prices by up to 1,000%, suggesting that he might use trade leverage to compel action.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Presented by AstraZeneca{beacon} Health Care Health Care   The Big Story CMS targets hospitals with site-neutral drug ruleThe ...

The so-called "One, Big Beautiful Bill" includes the largest cuts to Medicaid in the program's 50-plus years. What to know in Alabama.